[go: up one dir, main page]

WO2000034475A3 - Grnf4, a gdnf-related neurotrophic factor - Google Patents

Grnf4, a gdnf-related neurotrophic factor Download PDF

Info

Publication number
WO2000034475A3
WO2000034475A3 PCT/US1999/028975 US9928975W WO0034475A3 WO 2000034475 A3 WO2000034475 A3 WO 2000034475A3 US 9928975 W US9928975 W US 9928975W WO 0034475 A3 WO0034475 A3 WO 0034475A3
Authority
WO
WIPO (PCT)
Prior art keywords
grnf4
neurotrophic factor
gdnf
gfrα
present
Prior art date
Application number
PCT/US1999/028975
Other languages
French (fr)
Other versions
WO2000034475A2 (en
WO2000034475A9 (en
Inventor
William Scott Simonet
Franklin J Asuncion
Hosung Min
Shuqian Jing
Original Assignee
Amgen Inc
William Scott Simonet
Franklin J Asuncion
Hosung Min
Shuqian Jing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, William Scott Simonet, Franklin J Asuncion, Hosung Min, Shuqian Jing filed Critical Amgen Inc
Priority to EP99967225A priority Critical patent/EP1137774A2/en
Priority to JP2000586909A priority patent/JP2002531128A/en
Priority to AU23546/00A priority patent/AU2354600A/en
Publication of WO2000034475A2 publication Critical patent/WO2000034475A2/en
Publication of WO2000034475A3 publication Critical patent/WO2000034475A3/en
Publication of WO2000034475A9 publication Critical patent/WO2000034475A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to molecules referred to as GDNF-related neurotrophic factor 4 (GRNF4). The present invention involves the cloning, expression, characterization and use of GRNF4. Polynucleotide molecules and amino acid sequences are described for GRNF4. GRNF4 is 35 % identical to glial cell line-derived neurotrophic factor and 46 % identical to neurturin. GRNF4 binds to GFRα-3 which is a receptor of the GFRα family exclusively expressed in the peripheral sensory and sympathetic nervous systems.
PCT/US1999/028975 1998-12-09 1999-12-08 Grnf4, a gdnf-related neurotrophic factor WO2000034475A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99967225A EP1137774A2 (en) 1998-12-09 1999-12-08 Grnf4, a gdnf-related neurotrophic factor
JP2000586909A JP2002531128A (en) 1998-12-09 1999-12-08 Neurotrophic factor GRNF4
AU23546/00A AU2354600A (en) 1998-12-09 1999-12-08 Grnf4 a neurotrophic factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11162698P 1998-12-09 1998-12-09
US60/111,626 1998-12-09

Publications (3)

Publication Number Publication Date
WO2000034475A2 WO2000034475A2 (en) 2000-06-15
WO2000034475A3 true WO2000034475A3 (en) 2000-11-09
WO2000034475A9 WO2000034475A9 (en) 2002-08-29

Family

ID=22339556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028975 WO2000034475A2 (en) 1998-12-09 1999-12-08 Grnf4, a gdnf-related neurotrophic factor

Country Status (4)

Country Link
EP (1) EP1137774A2 (en)
JP (1) JP2002531128A (en)
AU (1) AU2354600A (en)
WO (1) WO2000034475A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
JP4469500B2 (en) † 1998-07-14 2010-05-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Neurotrophic growth factor
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
KR100872807B1 (en) * 2001-02-01 2008-12-09 바이오겐 아이덱 엠에이 인코포레이티드 Polymer conjugates of nublastin and methods of use thereof
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ES2374971T3 (en) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. USE OF NEUBLASTINE POLYPEPTIDES FOR THE TREATMENT OF NEUROPATHIC PAIN.
EP1417336A4 (en) * 2001-07-15 2005-06-22 Keck Graduate Inst EXPONENTIAL AMPLIFICATION OF NUCLEIC ACIDS USING CUTTING ENDONUCLEASES
MXPA05008168A (en) * 2003-01-31 2005-10-05 Biogen Idec Inc Polymer conjugates of mutated neublastin.
ATE472333T1 (en) 2004-08-19 2010-07-15 Biogen Idec Inc REFOLDING OF TRANSFORMING GROWTH FACTOR BETA FAMILY PROTEINS
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
TWI445544B (en) 2007-05-01 2014-07-21 Biogen Idec Inc Compositions and methods for increasing vascularization
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
RU2730864C1 (en) * 2017-11-10 2020-08-26 Редженесис Сайенс Ко., Лтд. Method of producing cultured cells and medicinal preparation for treating spinal injuries

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033912A2 (en) * 1996-03-14 1997-09-18 Genentech, Inc. Uses of gdnf and gdnf receptor
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
WO2000017360A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033912A2 (en) * 1996-03-14 1997-09-18 Genentech, Inc. Uses of gdnf and gdnf receptor
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
WO2000017360A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BALOH R. H. ET AL.: "ARTEMIN, A NOVEL MEMBER OF THE GDNF LIGAND FAMILY, SUPPORTS PERIPHERAL AND CENTRAL NEURONS AND SIGNALS THROUGH THE GFRALPHA3- RET RECEPTOR COMPLEX", NEURON, vol. 21, no. 6, December 1998 (1998-12-01), pages 1291 - 1302, XP000857438 *
MASURE S. ET AL.: "ENOVIN, A MEMBER OF THE GLIAL CELL-LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) FAMILIY WITH GROWTH PROMOTING ACTIVITY ON NEURONAL CELLS", EUROPEAN JOURNAL OF BIOCHEMISTRY,DE,BERLIN, vol. 266, no. 3, 1999, pages 892 - 902, XP000882986, ISSN: 0014-2956 *
See also references of EP1137774A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
JP2002531128A (en) 2002-09-24
WO2000034475A2 (en) 2000-06-15
EP1137774A2 (en) 2001-10-04
AU2354600A (en) 2000-06-26
WO2000034475A9 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2000034475A3 (en) Grnf4, a gdnf-related neurotrophic factor
UA40587C2 (en) METHANESULFONATE (E)-3-<font face="Symbol">[</font>2-N-BUTYL-1-{(4-CARBOXYPHENYL)METHYL}-1N-IMIDAZOLE-5-YL<font face="Symbol">]</font>-2-(2-THIENYL)METHYL-2-PROPIONIC ACID, PROCESS FOR OBTAINING THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
HUP9902640A2 (en) Glial cell line-derived neurotrophic factor receptor
IL143402A0 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
HU9600449D0 (en) Protocadherin proteins and their uses
EP1903112A3 (en) Activin receptors-like kinase(alk), belonging to the TGF receptor family and/or to the BMP receptor family
WO2001062726A3 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
WO2000001815A3 (en) Neurotrophic factors
IL113979A0 (en) Process for preparing cardiodilatin fragments highly purified cardiodilatin fragments and intermediate products for the preparation of same
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
CA2295999A1 (en) Nik proteins, nucleic acids and methods
HUP9701193A3 (en) Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
WO2001061007A3 (en) Fibroblast growth factor-23 molecules and uses thereof
WO2001055411A3 (en) Human sulfatases
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
EP1970099A3 (en) Process for relaxing or straightening hair
WO1998020029A3 (en) Hnf3-delta compositions
WO1994014960A3 (en) Protocadherin, their autibodies and uses
WO2003062268A3 (en) Corticotropin releasing factor receptor 2 agonists
DE69713048D1 (en) Process for the production of very pure isobutene that reactive distillation combines hydroisomerization, distillation and carbon skeleton isomerization
WO2001042474A3 (en) Interferon-like molecules and uses thereof
YU41798A (en) Scf analogous compositions and methods
ATE342363T1 (en) PURIFIED PROTEINS, RECOMBINANT DNA SEQUENCES AND PROCESSES FOR THE PRODUCTION OF CAFFEINE-FREE BEVERAGES
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586909

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999967225

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967225

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/24-24/24, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE